Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A).

Tomomi KashiwadaKatsunori ShinozakiShohei UenoHirofumi KawanakaFutoshi UnoYoshihiro OkitaMasaru FukahoriHidenobu MatsushitaYasunori EmiMototsugu ShimokawaAkitaka MakiyamaHiroshi SaekiEiji OkiYoshihiko MaeharaMasaki MoriEishi Babanull null

Published in: International journal of clinical oncology (2020)

This study represents the first evaluation of SOX130 in patients with HER2-negative AGC. SOX130 showed an acceptable safety profile, but the prespecified statistical efficacy targets were not achieved.

Keyphrases

combination therapy
transcription factor
stem cells
papillary thyroid
locally advanced
squamous cell
clinical trial
rectal cancer